Oxford BioMedica

What Oxford BioMedica does

Oxford BioMedica PLC (LSE: OXB), trading as OXB, is a UK-headquartered, publicly listed Contract Development and Manufacturing Organization (CDMO) founded in 1995 as a spin-out from the University of Oxford. The company specializes in the development and GMP manufacture of viral vectors — lentivirus, AAV, adenovirus, MVA, and other viral vectors — used in cell and gene therapies, vaccines, and oncolytic applications. OXB operates an integrated, end-to-end service model spanning process development, GMP manufacturing (bioreactor scales from 200L to 2,000L), analytical methods (55+ validated assays), and regulatory support (30+ IND submissions, products approved in 40+ countries). The technology backbone comprises proprietary platforms including LentiVector™ (3rd/4th generation lentiviral systems with TetraVecta™, TRiP System™, SupA-LTR™, MaxPax™, LentiStable™ cell lines), inAAVate™ AAV platform (dual plasmid system achieving up to 10x industry-standard bioreactor titres, 90% full capsids, GMP AAV in as little as 7 months), and AdenoVate™ for adenoviral vectors (validated at >100M COVID-19 vaccine doses). OXB's LentiVector™ platform was used to manufacture the world's first approved CAR-T therapy.

OXB generates revenue through professional-services fee-for-service contracts with pharmaceutical and biotechnology companies developing cell and gene therapies, with pricing determined via project-specific quotes and multi-year contract cadence. Its customer base includes BMS, Novartis, AstraZeneca, Boehringer Ingelheim, Kyverna, Arcellx, Cabaletta Bio, and Orchard Therapeutics. The company operates a tri-continental manufacturing footprint across five UK sites (Oxford, Wallingford, Yarnton; 17,030m²), two US facilities (Bedford MA, Durham NC; ~20,160m²), two French sites acquired via ABL Europe (Lyon, Strasbourg; 11,400m²), and an Ireland support office. As of December 2025, OXB had 950+ employees. Following the January 2024 acquisition of ABL Europe, the October 2025 acquisition of an FDA-approved Durham facility, and a $125 million loan facility from Oaktree Capital Management, OXB reported FY 2025 revenue of £170.9 million (33% YoY growth), its first full year of Operating EBITDA profitability (£8.1 million vs. £15.3 million loss in FY 2024), and a £204 million revenue backlog (+36% YoY). Management guidance for FY 2026 is £220–240 million, with a stated 2030 revenue ambition of approximately £500 million.

Name

Oxford BioMedica

Legal name

Oxford Biomedica PLC

Website

https://oxb.com

Company type

Public

Founded year

1995

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Oxford BioMedica is a UK-listed CDMO specializing in GMP manufacturing of lentiviral, AAV, and adenoviral vectors for cell and gene therapy developers, serving pharma and biotech clients globally from pre-clinical through commercial launch.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Contract Development and Manufacturing (CDMO) for Viral Vectors

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Gene Therapy CDMO (Viral Vector Manufacturing) (HLAGAGAB)

akta.pro secondary industries

Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE), Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral) (HLAAAKAD), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

Keywords

• Viral vector manufacturing
• Cell gene therapy CDMO
• Lentiviral vector production
• AAV manufacturing services
• GMP contract manufacturing

Headquarters

HQ city

Oxford

HQ country

United Kingdom

HQ region

Europe

Offices10 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain

Revenue model

1. CDMO Services - Contract Manufacturing: Oxford BioMedica operates as a Contract Development and Manufacturing Organization (CDMO), providing fee-for-service viral vector manufacturing and development services to pharmaceutical and biotech clients across lentivirus, AAV, adenovirus and other viral vectors. Revenue is generated through project-based contracts for process development, GMP manufacturing, analytical methods, and regulatory support services.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Oxford BioMedica is a global CDMO providing fee-for-service viral vector development and GMP manufacturing for cell and gene therapy clients. Its offering spans proprietary platforms (LentiVector™ for lentivirus, inAAVate™ for AAV, AdenoVate™ for adenovirus) and end-to-end services including process development, GMP manufacturing at 200L–2,000L bioreactor scale, analytical methods, regulatory support, and fill/finish across UK, US, and France facilities.

Product overview

OXB (Oxford BioMedica) is a global quality and innovation-led Contract Development and Manufacturing Organization (CDMO) specializing in cell and gene therapy viral vectors. The company offers a portfolio of proprietary technology platforms—LentiVector™ for lentiviral vectors, inAAVate™ for AAV, and AdenoVate™ for adenovirus—alongside comprehensive CDMO services including process development, GMP manufacturing, analytical methods, and regulatory support. The architecture consists of platform-based solutions (for accelerated development), custom solutions (modular services), and tech-transfer services. Supporting offerings include the Fast-track Development Offering for expedited timelines and the VectorXcellerator Programme for early-stage programme support. With facilities across the UK, France, and US, OXB supports clients from pre-clinical through to commercial launch.

Differentiator

Problem solved

Functional benefit

Brands

• LentiVector™ platform: Proprietary platform for lentiviral vector development and manufacturing, encompassing vector design, upstream and downstream processing, analytics, and fill/finish services
• inAAVate™ platform
• TetraVecta™ system
• VectorXcellerator Programme

Products and services

• LentiVector™ platform Proprietary lentiviral vector platform providing scalable production of high-quality lentiviral vectors for cell and gene therapies, offering 3rd and 4th generation vector systems including TetraVecta™, 2KO genome™, SupA-LTR™, MaxPax™, and TRiP System™ innovations. Used by OXB as the foundation of its lentivirus CDMO offering for pharmaceutical and biotech clients.
• inAAVate™ platform Proprietary AAV manufacturing platform that can deliver GMP AAV in as little as 7 months, featuring a dual-plasmid system that increases bioreactor titre up to 10-fold over industry standards and achieves market-leading full-to-empty capsid ratios. Licensed to clients including VVMF in Asia-Pacific.
• AdenoVate™ platform Platform for adenovirus development and manufacturing, including chimpanzee adenovirus (ChAdOx1) and other adenoviral platforms, demonstrated at scale with over 100 million doses of the Oxford-AstraZeneca COVID-19 vaccine manufactured.
• MVA (Modified Vaccinia Ankara) vectors Viral vectors based on Modified Vaccinia Ankara for immuno-oncology and infectious disease vaccines, with capabilities spanning process development through GMP production and drug product fill-finish.
• Process Development Services End-to-end process development services for viral vectors including serum-free suspension process development, parameter optimization, and integrated lab-to-launch support ensuring high-yield, reproducible, and scalable processes for pharmaceutical and biotech clients.
• GMP Manufacturing Services World-class GMP manufacturing for viral vectors with global presence in UK, US, and France, supporting clinical and commercial supply with bioreactor systems from 200L to 2,000L and integrated fill-finish capabilities.
• Analytical Methods Services Comprehensive viral vector analytics with 55+ validated methods including potency, identity, purity, quantity, and safety assays, with purpose-built BSL-3 facilities for RCL testing. Around 90% of analytical assays are performed in-house for AAV.
• Regulatory Support Services End-to-end regulatory services from consultation to full authorship of filings, supporting IND, CTA, MAA, and BLA submissions with over 30 successful IND submissions and products approved in 40+ countries.
• Fast-track Development Offering Expedited development and manufacturing service using proprietary inAAVate™ and LentiVector™ platforms that can accelerate AAV timeline to GMP from ~15 months to as little as 7 months, and lentiviral vector timeline to as little as 9 months. Designed for biotech clients with timeline constraints.
• VectorXcellerator Programme Fully funded feasibility studies supporting early-stage cell and gene therapy programmes, with no obligation for future commercial engagement, leveraging OXB's inAAVate™ and LentiVector™ platforms. Applications for the 2026 cycle were open.

Quantifiable outcome

• GMP AAV delivered in as little as 7 months (vs industry standard ~15 months)
• +6 more outcomes

Named customers8 records

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Bristol Myers SquibbcoreStrategic or Co-development Partner · 4 February 2026Multi-year commercial supply agreement for manufacture and supply of lentiviral vectors for BMS CAR-T cell therapy programmes. Initial five-year term with option to extend. Manufacturing will occur at OXB facilities in Oxford, UK and Durham, NC, with commercial production expected to begin in 2026 pending regulatory approval.
• University of OxfordcoreStrategic or Co-development PartnerOXB was founded as a spin-out from University of Oxford in 1995. Ongoing collaboration through BBSRC-funded ABViP doctoral training programme, Advanced Bioscience of Viral Products.
• University College LondonminorStrategic or Co-development PartnerCollaboration through ABViP (Advanced Bioscience of Viral Products) BBSRC-funded Collaborative Training Partnership doctoral programme.

Scale indicators23 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• AGC Biologics: Global CDMO offering viral vector, cell therapy, and biologics manufacturing services from clinical to commercial scale. Directly comparable in customer segment (pharma/biotech cell and gene therapy developers) and capability mix.
• Catalent: Global biologics CDMO with significant viral vector and gene therapy manufacturing capabilities across lentivirus and AAV. Closely comparable to OXB in customer base (pharma/biotech cell and gene therapy developers) and service offering (process development through GMP fill-finish).
• BioReliance (Merck KGaA / MilliporeSigma): Merck's CDMO services arm offering viral vector manufacturing, biosafety testing, and process development. Directly comparable service portfolio and target customers in cell and gene therapy development.
• WuXi AppTec / WuXi Biologics: Asia-headquartered CDMO with growing viral vector and cell therapy capabilities; competes with OXB particularly in EU and US pharma accounts seeking large-scale gene therapy manufacturing.
• Rentschler Biopharma: European biologics CDMO led by former OXB CEO's previous employer; offers process development and GMP manufacturing including viral vectors for cell and gene therapy. Highly comparable client base and service model.

Broad incumbents

• Lonza Group: Largest pure-play CDMO with broad biologics and cell/gene therapy services including viral vector manufacturing. Competes with OXB in lentiviral and AAV manufacturing but operates at much larger scale across many modalities.
• Charles River Laboratories: Major CRO/CDMO with viral vector and cell therapy manufacturing capabilities as part of its broader discovery-to-manufacturing services. Competes with OXB for biotech CDMO contracts across the cell/gene therapy value chain.
• Samsung Biologics: Large-scale biologics CDMO expanding into viral vector and gene therapy manufacturing services. Competes with OXB primarily on commercial-scale capacity for pharma clients.
• Thermo Fisher Scientific (Patheon/CDMO Services): Diversified life sciences giant whose pharma services division offers viral vector, plasmid, and cell therapy manufacturing. Competes for the same pharma CDMO contracts as OXB with a much broader portfolio.

Emerging players

• Vibalogics (Recipharm): Specialist viral vector CDMO focused on late-stage clinical and commercial GMP manufacturing for oncolytic, vaccine, and gene therapy vectors. Comparable niche focus and customer base to OXB, though smaller in scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/user/OxfordBioMedica
• LinkedInlinkedin.com/company/oxford-biomedica
• Xx.com/oxfordbiomedica

Revenue estimate

Valuation estimate

Number of profiles

Profiles19 records

Subsidiaries2 records

Funding overview

Funding rounds6 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oxford BioMedica